OPKO Health announced that the last patient has completed the final visit in the company’s pivotal phase 3 study evaluating the safety and efficacy of the once weekly somatrogon (hGH─CTP) for treatment of growth hormone deficiency in children.
OPKO Health announced that the last patient has completed the final visit in the company’s pivotal phase 3 study evaluating the safety and efficacy of the once weekly somatrogon (hGH─CTP) for treatment of growth hormone deficiency in children.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
